Determinants of Renal Volume in Autosomal-dominant Polycystic Kidney Disease

Overview

Journal Kidney Int

Publisher Elsevier

Specialty Nephrology

Date 2007 Oct 26

PMID 17960141

Citations 53

Authors

J J Grantham

L T Cook

V E Torres

J E Bost

A B Chapman

P C Harris

L M Guay-Woodford

K T Bae

Affiliations

Soon will be listed here.

Abstract

The Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) recently showed that renal enlargement in autosomal-dominant polycystic kidney disease mimicked exponential growth. We determined the effects of cyst initiation rate, total number, and growth rate on the time-dependent change of total cyst volume (TCV). Mathematical models with equations integrating cyst surface area, volume, and an invariant growth rate constant were used to compute the time-dependent change in volume of solitary and multiple cysts. Multiple expanding cysts increased TCV in an exponential-like pattern even when individual cysts formed at different rates or exhibited different but constant growth rates. TCV depended on the rate of cyst initiation and on the total number of cysts; however, the compounding effect of exponential-like growth was the most powerful determinant of long-term cyst expansion. Extrapolation of TCV data plots for individual subjects back to an age of 18 predicted TCV values within an established range. We conclude that cysts started early in life were the main contributor to eventual TCV while their growth rate primarily determined renal size; although the rate of formation and the ultimate number of cysts also contributed. The good fit between the exponential models and the extrapolated CRISP data indicates that the TCV growth rate is a defining trait for individual patients and may be used as a prognostic marker.

Citing Articles

Characteristics of patients with autosomal polycystic kidney disease reaching kidney failure by age 40.

Wigerinck S, Schellekens P, Smith B, Hanna C, Dachy A, Chedid M Pediatr Nephrol. 2025; .

PMID: 39891678 DOI: 10.1007/s00467-024-06652-7.

Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial.

Higashihara E, Matsukawa M, Jiang H Clin Exp Nephrol. 2025; .

PMID: 39747793 DOI: 10.1007/s10157-024-02589-1.

Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

St Pierre K, Cashmore B, Bolignano D, Zoccali C, Ruospo M, Craig J Cochrane Database Syst Rev. 2024; 10:CD010294.

PMID: 39356039 PMC: 11445802. DOI: 10.1002/14651858.CD010294.pub3.

How histopathological diagnosis interacts with kidney ultrasound parameters and glomerular filtration rate.

Andrulli S, Gigante A, Rossini M, DAngio P, Vischini G, Luchetta F Intern Emerg Med. 2024; 19(8):2121-2132.

PMID: 39269540 PMC: 11582157. DOI: 10.1007/s11739-024-03711-7.

Single-Center Experience of Pediatric Cystic Kidney Disease and Literature Review.

Grlic S, Gregurovic V, Martinic M, Davidovic M, Kos I, Galic S Children (Basel). 2024; 11(4).

PMID: 38671609 PMC: 11048964. DOI: 10.3390/children11040392.

References

Bae K, Commean P, Lee J . Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr. 2000; 24(4):614-9. DOI: 10.1097/00004728-200007000-00019. View

Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P . Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003; 14(5):1164-74. DOI: 10.1097/01.asn.0000061774.90975.25. View

Grantham J . Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int. 2003; 64(4):1157-62. DOI: 10.1046/j.1523-1755.2003.00242.x. View

Brasier J, Henske E . Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest. 1997; 99(2):194-9. PMC: 507786. DOI: 10.1172/JCI119147. View

Macdermot K, Saggar-Malik A, Economides D, Jeffery S . Prenatal diagnosis of autosomal dominant polycystic kidney disease (PKD1) presenting in utero and prognosis for very early onset disease. J Med Genet. 1998; 35(1):13-6. PMC: 1051180. DOI: 10.1136/jmg.35.1.13. View

Belibi F, Reif G, Wallace D, Yamaguchi T, Olsen L, Li H . Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004; 66(3):964-73. DOI: 10.1111/j.1523-1755.2004.00843.x. View

Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B . Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005; 68(1):206-16. DOI: 10.1111/j.1523-1755.2005.00395.x. View

Gattone 2nd V, Wang X, Harris P, Torres V . Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003; 9(10):1323-6. DOI: 10.1038/nm935. View

Yamaguchi T, Pelling J, Ramaswamy N, Eppler J, Wallace D, Nagao S . cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000; 57(4):1460-71. DOI: 10.1046/j.1523-1755.2000.00991.x. View

10.

Welling L, Welling D . Theoretical models of cyst formation and growth. Scanning Microsc. 1988; 2(2):1097-102. View

11.

CUPPAGE F, Huseman R, Chapman A, Grantham J . Ultrastructure and function of cysts from human adult polycystic kidneys. Kidney Int. 1980; 17(3):372-81. DOI: 10.1038/ki.1980.43. View

12.

El-Merhi F, Bae K . Cystic renal disease. Magn Reson Imaging Clin N Am. 2004; 12(3):449-67, vi. DOI: 10.1016/j.mric.2004.03.009. View

13.

Lu W, Fan X, Basora N, Babakhanlou H, Law T, Rifai N . Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet. 1999; 21(2):160-1. DOI: 10.1038/5944. View

14.

Grantham J, Geiser J, Evan A . Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 1987; 31(5):1145-52. DOI: 10.1038/ki.1987.121. View

15.

SULLIVAN L, Wallace D, Grantham J . Epithelial transport in polycystic kidney disease. Physiol Rev. 1998; 78(4):1165-91. DOI: 10.1152/physrev.1998.78.4.1165. View

16.

Qian F, Watnick T, Onuchic L, Germino G . The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell. 1996; 87(6):979-87. DOI: 10.1016/s0092-8674(00)81793-6. View

17.

Grantham J . Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis. 1990; 15(2):110-6. DOI: 10.1016/s0272-6386(12)80507-5. View

18.

Wallace D, Grantham J, SULLIVAN L . Chloride and fluid secretion by cultured human polycystic kidney cells. Kidney Int. 1996; 50(4):1327-36. DOI: 10.1038/ki.1996.445. View

19.

Huseman R, Grady A, Welling D, Grantham J . Macropuncture study of polycystic disease in adult human kidneys. Kidney Int. 1980; 18(3):375-85. DOI: 10.1038/ki.1980.148. View

20.

Grantham J, Uchic M, Cragoe Jr E, Kornhaus J, Grantham J, Donoso V . Chemical modification of cell proliferation and fluid secretion in renal cysts. Kidney Int. 1989; 35(6):1379-89. DOI: 10.1038/ki.1989.137. View